NovoCure Limited (NVCR) Just Recorded A Sigfniciant Increase

April 26, 2018 - By Linda Rogers

The stock of NovoCure Limited (NASDAQ:NVCR) is a huge mover today! The stock increased 9.94% or $2.4 during the last trading session, reaching $26.55. About 1.73 million shares traded or 87.16% up from the average. NovoCure Limited (NASDAQ:NVCR) has risen 174.34% since April 26, 2017 and is uptrending. It has outperformed by 162.79% the S&P500.
The move comes after 9 months positive chart setup for the $2.40B company. It was reported on Apr, 26 by We have $28.67 PT which if reached, will make NASDAQ:NVCR worth $192.00 million more.

NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields for the treatment of solid tumors. The company has market cap of $2.40 billion. The firm markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It currently has negative earnings. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.